复发胶质母细胞瘤再程放疗:单中心回顾性队列研究
该单中心回顾性研究纳入59例复发胶质母细胞瘤(rGBM)患者,分析再程放疗的疗效与安全性。中位无进展生存期(PFS)为5.9个月,疾病控制率83.6%,未观察到3-5级急性再程放疗相关不良事件,放射性坏死(RN)发生率为16.9%。同步化疗或抗VEGF治疗与改善结局显著相关(p=0.049),贝伐珠单抗在预防RN和增强疗效方面均有前景。
要点
- rGBM再程放疗中位PFS 5.9个月,疾病控制率83.6%,未发生3-5级急性不良事件。
- 放射性坏死发生率16.9%,同步抗VEGF治疗者发生率显著较低。
- 同步化疗或抗VEGF治疗与改善结局显著相关(p=0.049),贝伐珠单抗具双重潜力。
核心结论
- 复发胶质母细胞瘤再程放疗可行且安全,在选定患者中带来潜在PFS获益。
- 贝伐珠单抗是特别有前景的联合搭档,兼有预防放射性坏死和增强疗效的潜力。
研究设计与样本
- 单中心回顾性队列研究,连续纳入近10年接受至少一程额外颅脑放疗的59例GBM(CNS WHO 4级,IDH野生型)患者。
- 主要终点为PFS,次要终点包括再程放疗相关不良事件率,尤其关注放射性坏死。
主要发现
- 再程放疗后中位随访8.7(0.5-48.0)个月,首次复发中位时间15(4-89)个月,多数为野内复发(59.7%)。
- 疾病控制率83.6%,中位PFS 5.9(0.5-48.0)个月。
- 未观察到3-5级急性再程放疗相关不良事件;放射性坏死诊断率16.9%(80%为2级,20%为3级),同步抗VEGF治疗者发生率显著较低。
- 放射性坏死风险与再程放疗体积或剂量无关(p=0.15和p=0.43)。
- 同步化疗或抗VEGF治疗与改善结局显著相关(p=0.049),较小再程放疗体积显示PFS延长的非显著趋势(p=0.23)。
关键数值与推荐
- 再程放疗EQD2⍺/β=10范围为31.3-80.2 Gy,中位处方剂量42 Gy。
- 81.4%的患者再程放疗联合全身治疗。
临床怎么用
- 对选定rGBM患者可考虑再程放疗,需关注放射性坏死风险。
- 同步贝伐珠单抗等抗VEGF治疗可能降低放射性坏死并改善疗效。
- 再程放疗体积或剂量与放射性坏死风险无关,但较小体积可能有PFS获益趋势。
局限性
- 回顾性单中心设计,样本量有限(59例),随访时间范围宽。
- 部分复发病灶为疑似而非组织病理学确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The management of recurrent glioblastoma (rGBM) remains a clinical challenge, with only limited therapeutic options available to date. Reirradiation may offer a progression-free survival (PFS) benefit in selected cases, but data are scarce. METHODS: Consecutive patients from the last 10 years with GBM (CNS WHO grade 4, IDH-wildtype) who underwent at least one additional course of cranial radiotherapy for suspected or histopathologically confirmed rGBM at a tertiary neuro-oncological center were retrospectively analyzed. The primary endpoint was PFS, secondary endpoints included reirradiation-related adverse event rates, with a particular focus on radiation necrosis (RN). RESULTS: Fifty-nine patients were included with a median follow-up (range) of 8.7 (0.5-48.0) months after reirradiation. The median time to first recurrence was 15 (4-89) months, with the majority occurring in-field (59.7 %). The EQD2⍺/β=10 ranged from 31.3-80.2 Gy with a median prescription dose of 42 Gy. Reirradiation was combined with systemic therapy in 81.4 % of patients. No grade 3-5 acute reirradiation-related adverse events were observed. RN was diagnosed in 16.9 % of patients (80 % grade 2 and 20 % grade 3), with a notably low rate in those receiving anti-VEGF therapy parallel to reirradiation. RN risk was independent of reirradiation volume or dose (p = 0.15 and 0.43, respectively). The disease control rate following reirradiation was 83.6 % and the median PFS was 5.9 (0.5-48.0) months. Concomitant chemotherapy or anti-VEGF therapy was significantly associated with improved outcomes (p = 0.049), whereas smaller reirradiation volumes demonstrated a non-significant trend towards longer PFS (p = 0.23). CONCLUSION: In this retrospective analysis, reirradiation for rGBM was feasible and safe, conferring a potential PFS benefit in selected patients. Bevacizumab emerged as a particularly promising combination partner, contributing to both RN prevention and enhanced efficacy.
引用
- Dejonckheere CS, Zeyen T, Duffy C, et al. Reirradiation of recurrent glioblastoma: Results from a single-center retrospective cohort study. Clin Transl Radiat Oncol. 2025. PMID: 40821395. doi:10.1016/j.ctro.2025.101029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。